213 related articles for article (PubMed ID: 10410229)
1. [New quinolones].
Bello Dronda S
Arch Bronconeumol; 1999 May; 35 Suppl 3():70-6. PubMed ID: 10410229
[No Abstract] [Full Text] [Related]
2. [New quinolones for the treatment of community-acquired pneumonia--pro].
Zimmerli S
Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859
[No Abstract] [Full Text] [Related]
3. [New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M
Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
[No Abstract] [Full Text] [Related]
4. [The place of the new quinolones in the guidelines on the treatment of community-acquired pneumonia].
Dorca J
Arch Bronconeumol; 1999 May; 35 Suppl 3():77-80. PubMed ID: 10410230
[No Abstract] [Full Text] [Related]
5. [New quinolones].
Kakeya H; Fukushima K; Saito A
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():542-8. PubMed ID: 17455678
[No Abstract] [Full Text] [Related]
6. Drug not considered a first-line agent.
Lexchin J
Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049
[No Abstract] [Full Text] [Related]
7. New antibiotic approved for community-acquired infections.
Nurse Pract; 1998 Jan; 23(1):94. PubMed ID: 9470200
[No Abstract] [Full Text] [Related]
8. New generations of quinolones: with particular attention to levofloxacin.
Ambrose PG; Owens RC; Quintiliani R; Nightingale CH
Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076
[No Abstract] [Full Text] [Related]
9. Pneumonia observational incidence and treatment: a multidisciplinary process improvement study.
Brozek J; McDonald E; Clarke F; Gosse C; Jaeschke R; Cook D
Am J Crit Care; 2007 May; 16(3):214-9. PubMed ID: 17460312
[TBL] [Abstract][Full Text] [Related]
10. Aspiration pneumonia.
Dreyfuss D; Mier L
N Engl J Med; 2001 Jun; 344(24):1868-9; author reply 1869-70. PubMed ID: 11407356
[No Abstract] [Full Text] [Related]
11. Lomefloxacin sensitivities.
Smith JM; Hashmi ZS
N Z Med J; 1989 Jul; 102(872):391. PubMed ID: 2797570
[No Abstract] [Full Text] [Related]
12. [Antimicrobial activity of ciprofloxacin and netilmicin compared to various antibiotics in Lome, Togo].
Dagnra AY; Prince-David M; Hounkpati A
Sante; 2001; 11(1):63-6. PubMed ID: 11313234
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L
Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351
[TBL] [Abstract][Full Text] [Related]
14. [Quinolones. Gyrase inhibitors].
Höffler D
Internist (Berl); 1994 May; 35(5):484-9. PubMed ID: 8021119
[No Abstract] [Full Text] [Related]
15. In vitro antimicrobial interactions of arthemeter with some 4-quinolones.
Esimone CO; Adikwu MU; Nwafor SV; Okoli CO; Ndu OO; Nwoke OI
Boll Chim Farm; 2002; 141(5):385-8. PubMed ID: 12481382
[TBL] [Abstract][Full Text] [Related]
16. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
Montanari MP; Mingoia M; Varaldo PE
Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for severe infections: are they useful?
Cinel I; Dellinger RP
Curr Opin Crit Care; 2006 Oct; 12(5):483-8. PubMed ID: 16943730
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia.
Bradford PA; Petersen PJ; Tuckman M; Jones CH
Clin Microbiol Infect; 2008 Sep; 14(9):882-6. PubMed ID: 18844692
[TBL] [Abstract][Full Text] [Related]
19. Novel targets in the management of pneumonia.
Díaz LA; Mortensen EM; Anzueto A; Restrepo MI
Ther Adv Respir Dis; 2008 Dec; 2(6):387-400. PubMed ID: 19124384
[TBL] [Abstract][Full Text] [Related]
20. Quinolones: which generation for which microbe?
Lee MK; Kanatani MS
West J Med; 1999 Jun; 170(6):359-61. PubMed ID: 10443165
[No Abstract] [Full Text] [Related]
[Next] [New Search]
